CorTec's Brain-Computer Interface Achieves Second Successful Implantation

CorTec GmbH has announced the successful second implantation of its Brain-Computer Interface system, Brain Interchange™, at Harborview Medical Center, Seattle. This event forms part of an FDA-approved study on stroke patients, following promising results from the first participant. CorTec’s innovative platform aims to aid stroke recovery through precise neurotherapeutic interventions.

The trial, supported by the National Institutes of Health, is led by experts from the University of Washington and UCLA. It investigates direct cortical electrical stimulation for motor recovery. This second procedure reinforces the safety and potential efficacy of CorTec’s closed-loop BCI platform, enhancing rehabilitation by boosting neuroplasticity.

Dr. Frank Desiere, CEO of CorTec, highlighted this achievement as crucial in developing neurotherapeutic solutions for neurological conditions. The study will continue, aiming to further validate CorTec’s approach.